33.50
+1.34(+4.17%)
Currency In USD
| Previous Close | 32.16 |
| Open | 32 |
| Day High | 33.55 |
| Day Low | 31.5 |
| 52-Week High | 36.84 |
| 52-Week Low | 12.84 |
| Volume | 1.26M |
| Average Volume | 2.93M |
| Market Cap | 5.21B |
| PE | -335 |
| EPS | -0.1 |
| Moving Average 50 Days | 29.75 |
| Moving Average 200 Days | 21.56 |
| Change | 1.34 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $2,031.83 as of December 26, 2024 at a share price of $32.875. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $2,953.73 as of December 26, 2024 at a share price of $32.875.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TG Therapeutics to Participate in the Evercore HealthCONx Conference
GlobeNewswire Inc.
Nov 29, 2024 1:00 PM GMT
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ETNEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will pa
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
GlobeNewswire Inc.
Nov 21, 2024 11:00 AM GMT
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences,
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
GlobeNewswire Inc.
Nov 04, 2024 12:00 PM GMT
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE)